drugset / Trial / NCT03825887

Nalbuphine Versus Morphine for Mucositis Pain in Pediatric Cancer Patients

NCT03825887

Phase 3 Completed 80 enrolled Children's Cancer Hospital Egypt 57357
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Evaluation of safety and efficacy of Nalbuphine versus Morphine patient controlled analgesia (PCA) for mucositis pain in pediatric cancer patients

Timeline

Start
2018-02-01
Primary completion
2020-12-31
Completion
2020-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Morphine Other / unclassified 10 ug/kg
Subject Nalbuphine Small molecule 10 ug/kg